DiaMedica Therapeutics (NASDAQ: DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of $(0.18) per share from the same period last year.